SH 07 - Head and Neck Cancer - Science Highlights

Presentations

• 09:15am - 09:18am ET

  HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA) with Protons or Photons vs. Standard of Care for Head and Neck Squamous Cell Carcinoma: A Randomized Trial

  Speaker: Jos Elbers, MD, PhD - Erasmus Medical Center, Rotterdam
• 09:18am - 09:21am ET

  Pooled Analysis of Prospective Trials of FMISO PET-Guided 30Gy De-Escalation in HPV-Positive Oropharyngeal Cancer Demonstrating Reduced Toxicity with Durable Long-Term Control

  Speaker: Nancy Lee, MD, FASTRO - Memorial Sloan Kettering Cancer Center, New York
• 09:21am - 09:24am ET

  C-Post Study of Adjuvant Cemiplimab for High-Risk Cutaneous Squamous Cell Carcinoma: Impact of Adjuvant Radiotherapy on Disease-Free Survival

  Speaker: Gerard Adams, MB, ChB, FRANZCR - Genesis Care Bundaberg, Bundaberg
• 09:24am - 09:27am ET

  The HYPCON Trial 2: A Phase II Randomized Study Evaluating Hypofractionated vs. Conventional Adjuvant Concurrent Chemoradiation in Head and Neck Malignancies

  Speaker: Aarcha Ramadas, MBBS - AIIMS New Delhi, New Delhi
• 09:27am - 09:30am ET

  NRG-HN009 Randomized Phase II/III Trial of RT + Cisplatin Q3 Weeks vs RT + Cisplatin Weekly for Patients with Locoregionally Advanced SCCHN: p16-Negative Phase II Toxicity Results

  Speaker: Paul Harari, MD, FASTRO - University of Wisconsin School of Medicine and Public Health, Madison
• 09:30am - 09:33am ET

  Discussant

  Speaker: Michelle Mierzwa, MD - University of Michigan, Ann Arbor